What is the Origin of Somatostatin Receptor?

The name is derived from the hormone it binds, 'Somatostatin,' which was named for its initial discovery as a factor that inhibited the release of growth hormone (Somatotropin) from the pituitary gland. The receptor family was subsequently identified as the molecular machinery through which this inhibitory signal is transduced across the cell membrane.

What is the Mechanism of Somatostatin Receptor?

Upon the binding of somatostatin or a pharmaceutical analog to the $text{SSTr}$ on the cell surface, the receptor activates an inhibitory G protein ($text{G}_i$) within the cell. This activation cascade typically leads to a decrease in the intracellular concentration of cyclic AMP (cAMP) and a modulation of ion channel activity, resulting in the hyperpolarization of the cell membrane. The net physiological effect is a powerful inhibitory signal that suppresses the synthesis and secretion of the target hormone from the endocrine cell.

Somatostatin Receptor ∞ Area

Q: What is the Meaning of Somatostatin Receptor?

The Somatostatin Receptor ($text{SSTr}$) is a G protein-coupled receptor found on the cell surface of various endocrine and neuroendocrine tissues, including the pituitary gland, pancreas, and gastrointestinal tract, which mediates the powerful inhibitory effects of the peptide hormone somatostatin. Somatostatin acts as a universal regulatory brake, suppressing the secretion of numerous hormones, including growth hormone, insulin, and glucagon. The five distinct subtypes of this receptor, $text{SSTr1}$ through $text{SSTr5}$, are crucial targets for therapeutic agents used in the diagnosis and treatment of neuroendocrine tumors.

Somatostatin Receptor

Meaning

The Somatostatin Receptor (SSTr) is a G protein-coupled receptor found on the cell surface of various endocrine and neuroendocrine tissues, including the pituitary gland, pancreas, and gastrointestinal tract, which mediates the powerful inhibitory effects of the peptide hormone somatostatin. Somatostatin acts as a universal regulatory brake, suppressing the secretion of numerous hormones, including growth hormone, insulin, and glucagon. The five distinct subtypes of this receptor, SSTr1 through SSTr5, are crucial targets for therapeutic agents used in the diagnosis and treatment of neuroendocrine tumors.